Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01890993

Enrollment

952

Registered

2013-07-02

Start date

2013-08-31

Completion date

2014-06-30

Last updated

2015-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Diabetes Mellitus, Type 2

Brief summary

This study is conducted in Europe. The aim of this study is to demonstrate the clinical effectiveness and safety of liraglutide and dipeptidyl peptidase-4 (DPP-4) inhibitor therapy in routine primary care in Europe.

Interventions

DRUGliraglutide

Anonymised patient level data will be collected by the patients' own general practitioner and electronic case report form (eCRF) will be used to capture the data.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients treated with liraglutide or DPP-4 inhibitors, according to license in respective participating country with data available for 12 (+/- 2) months

Exclusion criteria

* Patients treated with liraglutide or DPP-4 inhibitors, outside of license in respective participating country

Design outcomes

Primary

Measure	Time frame
Change in HbA1c (glycosylated haemoglobin)	Baseline (anytime within 3 months before therapy initiation), month 12 (+/-2)

Secondary

Measure	Time frame
Change in body weight	Baseline (anytime within 3 months before therapy initiation), month 12 (+/-2)
Change in systolic blood pressure	Baseline (anytime within 3 months before therapy initiation), month 12 (+/-2)

Countries

France, Germany, Spain, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026